Belantamab Mafodotin Regimen Indicates Safety, Improved OS in Patients Treated With Multiple Myeloma
March 8th 2024Despite the belantamab mafodotin regimen improving overall survival in patients with relapsed or refractory multiple myeloma, the trial is ongoing to confirm the presented results.
Read More
Second-Line Bedaquiline-Based Regimens Demonstrates Microbiological Response in Patients With TB
March 4th 2024The regimen, which was used as second-line treatment in patients with drug-resistant TB, had a similar microbiological response to those with drug-sensitive TB taking first-line regimens.
Read More
FDA Accepts Priority Review for Linvoseltamab to Treat Adult Patients With R/R MM
February 22nd 2024Currently, the safety and efficacy of linvoseltamab in adult patients with relapsed or refractory multiple myeloma is being compared to elotuzumab, pomalidomide, and dexamethasone in a phase 3 clinical trial.
Read More
FDA Approves Omalizumab to Reduce Food-Based Allergic Reactions in Adult and Pediatric Patients
February 16th 2024This marks omalizumab’s fourth FDA-approved indication for allergic and inflammatory conditions, such as severe persistent allergic asthma, with its initial approval being in 2003.
Read More